Details of the Drug

General Information of Drug (ID: DMQ2FPC)

Drug Name
Vasopressin
Synonyms
Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP)
Indication
Disease Entry ICD 11 Status REF
Diabetes insipidus 5A61.5 Approved [1]
Enuresis 6C00 Approved [1]
Haemophilia A 3B10.0 Approved [2]
Nocturia MF55 Approved [2]
Polyuria MF55 Approved [1]
Von willebrand disease 3B12 Approved [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Vasoconstrictor Agents
Affected Organisms
Humans and other mammals
ATC Code
H01BA01: Vasopressin
H01BA: Vasopressin and analogues
H01B: POSTERIOR PITUITARY LOBE HORMONES
H01: PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 1084.2
Logarithm of the Partition Coefficient (xlogp) -4.8
Rotatable Bond Count (rotbonds) 19
Hydrogen Bond Donor Count (hbonddonor) 14
Hydrogen Bond Acceptor Count (hbondacc) 16
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The clearance of drug is 9-25 mL/min/kg in patients [4]
Elimination
Vasopressin is primarily eliminated in the urine, where only 6% of the dose is excreted unchanged [4]
Half-life
The concentration or amount of drug in body reduced by one-half in less than 10 minutes [4]
Metabolism
The drug is metabolized via serine proteases, carboxypeptidases, and disulphide oxidoreductases in the liver and kidneys [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.1 mg/mL [3]
Chemical Identifiers
Formula
C46H65N15O12S2
IUPAC Name
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
Canonical SMILES
C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
InChI
InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
InChIKey
KBZOIRJILGZLEJ-LGYYRGKSSA-N
Cross-matching ID
PubChem CID
644077
ChEBI ID
CHEBI:34543
CAS Number
113-79-1
UNII
Y87Y826H08
DrugBank ID
DB00067
TTD ID
D0N4OW
VARIDT ID
DR00247
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Agonist [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Vasopressin V1a receptor (AVPR1A) OTKR8AFL V1AR_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vasopressin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Vasopressin and Macimorelin. Pituitary gland disorder [5A60-5A61] [8]
Coadministration of a Drug Treating the Disease Different from Vasopressin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Vasopressin and Ivosidenib. Acute myeloid leukaemia [2A60] [9]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Midostaurin. Acute myeloid leukaemia [2A60] [10]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Idarubicin. Acute myeloid leukaemia [2A60] [10]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Daunorubicin. Acute myeloid leukaemia [2A60] [11]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Arn-509. Acute myeloid leukaemia [2A60] [12]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Gilteritinib. Acute myeloid leukaemia [2A60] [13]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Oliceridine. Acute pain [MG31] [10]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [10]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Tacrine. Alzheimer disease [8A20] [10]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Galantamine. Alzheimer disease [8A20] [10]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Rivastigmine. Alzheimer disease [8A20] [10]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Donepezil. Alzheimer disease [8A20] [10]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Vasopressin and Metronidazole. Amoebiasis [1A36] [14]
Ranolazine DM0C9IL Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Ranolazine. Angina pectoris [BA40] [15]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Vasopressin and Ivabradine. Angina pectoris [BA40] [12]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Vasopressin and Bepridil. Angina pectoris [BA40] [10]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Vasopressin and Dronedarone. Angina pectoris [BA40] [10]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Vasopressin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [16]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [10]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Promazine. Appearance/behaviour symptom [MB23] [10]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Cilostazol. Arterial occlusive disease [BD40] [10]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Voriconazole. Aspergillosis [1F20] [10]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Posaconazole. Aspergillosis [1F20] [10]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Levalbuterol. Asthma [CA23] [17]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Terbutaline. Asthma [CA23] [18]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Pirbuterol. Asthma [CA23] [18]
Isoetharine DMITSEH Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Isoetharine. Asthma [CA23] [18]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Salbutamol. Asthma [CA23] [17]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Formoterol. Asthma [CA23] [18]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [10]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [12]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Desipramine. Attention deficit hyperactivity disorder [6A05] [10]
Oxytocin DMDL27I Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Oxytocin. Autism spectrum disorder [6A02] [10]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Ofloxacin. Bacterial infection [1A00-1C4Z] [19]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [10]
Erythromycin DM4K7GQ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Erythromycin. Bacterial infection [1A00-1C4Z] [10]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Clarithromycin. Bacterial infection [1A00-1C4Z] [10]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Vasopressin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [10]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Vasopressin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [19]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [19]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Norfloxacin. Bacterial infection [1A00-1C4Z] [19]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Levofloxacin. Bacterial infection [1A00-1C4Z] [19]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Vasopressin and Moxifloxacin. Bacterial infection [1A00-1C4Z] [20]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [10]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Telithromycin. Bacterial infection [1A00-1C4Z] [10]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Retigabine. Behcet disease [4A62] [10]
Lamotrigine DM8SXYG Moderate Increased risk of hyponatremia by the combination of Vasopressin and Lamotrigine. Bipolar disorder [6A60] [14]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Eribulin. Breast cancer [2C60-2C6Y] [10]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Lapatinib. Breast cancer [2C60-2C6Y] [10]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Tamoxifen. Breast cancer [2C60-2C6Y] [10]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Vasopressin and Toremifene. Breast cancer [2C60-2C6Y] [10]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Bosutinib. Breast cancer [2C60-2C6Y] [12]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Vasopressin and Grepafloxacin. Bronchitis [CA20] [19]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Vasopressin and Sotalol. Cardiac arrhythmia [BC9Z] [10]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Vasopressin and Dofetilide. Cardiac arrhythmia [BC9Z] [10]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [21]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [18]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [17]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [18]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [18]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [18]
Phenylbutazone DMAYL0T Moderate Increased risk of hyponatremia by the combination of Vasopressin and Phenylbutazone. Chronic pain [MG30] [14]
Ketoprofen DMRKXPT Moderate Increased risk of hyponatremia by the combination of Vasopressin and Ketoprofen. Chronic pain [MG30] [14]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Levomilnacipran. Chronic pain [MG30] [14]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Oxaliplatin. Colorectal cancer [2B91] [10]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Isoproterenol. Conduction disorder [BC63] [17]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Halothane. Corneal disease [9A76-9A78] [10]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Propofol. Corneal disease [9A76-9A78] [22]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Sevoflurane. Corneal disease [9A76-9A78] [10]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Probucol. Coronary atherosclerosis [BA80] [10]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Vasopressin and Methadone. Cough [MD12] [10]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Clofazimine. Crohn disease [DD70] [23]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Vasopressin and Mifepristone. Cushing syndrome [5A70] [10]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Vasopressin and Pasireotide. Cushing syndrome [5A70] [10]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Osilodrostat. Cushing syndrome [5A70] [12]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Vasopressin and Sertraline. Depression [6A70-6A7Z] [14]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Trimipramine. Depression [6A70-6A7Z] [10]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Imipramine. Depression [6A70-6A7Z] [10]
Fluoxetine DM3PD2C Moderate Increased risk of hyponatremia by the combination of Vasopressin and Fluoxetine. Depression [6A70-6A7Z] [14]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Nortriptyline. Depression [6A70-6A7Z] [10]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Vasopressin and Vilazodone. Depression [6A70-6A7Z] [14]
Paroxetine DM5PVQE Moderate Increased risk of hyponatremia by the combination of Vasopressin and Paroxetine. Depression [6A70-6A7Z] [14]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Vasopressin and Vortioxetine. Depression [6A70-6A7Z] [14]
Duloxetine DM9BI7M Moderate Increased risk of hyponatremia by the combination of Vasopressin and Duloxetine. Depression [6A70-6A7Z] [14]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Milnacipran. Depression [6A70-6A7Z] [14]
Escitalopram DMFK9HG Moderate Increased risk of hyponatremia by the combination of Vasopressin and Escitalopram. Depression [6A70-6A7Z] [14]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Vasopressin and Desvenlafaxine. Depression [6A70-6A7Z] [14]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Clomipramine. Depression [6A70-6A7Z] [10]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Trazodone. Depression [6A70-6A7Z] [24]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Amitriptyline. Depression [6A70-6A7Z] [10]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Amoxapine. Depression [6A70-6A7Z] [10]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Protriptyline. Depression [6A70-6A7Z] [10]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Doxepin. Depression [6A70-6A7Z] [10]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Maprotiline. Depression [6A70-6A7Z] [10]
Fluvoxamine DMQTJSX Moderate Increased risk of hyponatremia by the combination of Vasopressin and Fluvoxamine. Depression [6A70-6A7Z] [14]
Venlafaxine DMR6QH0 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Venlafaxine. Depression [6A70-6A7Z] [14]
Citalopram derivative 1 DMITX1G Moderate Increased risk of hyponatremia by the combination of Vasopressin and Citalopram derivative 1. Discovery agent [N.A.] [14]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [10]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Deutetrabenazine. Dystonic disorder [8A02] [25]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Ingrezza. Dystonic disorder [8A02] [26]
Felbamate DM1V5ZS Moderate Increased risk of hyponatremia by the combination of Vasopressin and Felbamate. Epilepsy/seizure [8A61-8A6Z] [14]
Oxcarbazepine DM5PU6O Moderate Increased risk of hyponatremia by the combination of Vasopressin and Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [14]
Carbamazepine DMZOLBI Moderate Increased risk of hyponatremia by the combination of Vasopressin and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [14]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Vasopressin and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [14]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Solifenacin. Functional bladder disorder [GC50] [10]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Pentamidine. Fungal infection [1F29-1F2F] [10]
Fluconazole DMOWZ6B Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Fluconazole. Fungal infection [1F29-1F2F] [10]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Ketoconazole. Fungal infection [1F29-1F2F] [10]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Vasopressin and Cisapride. Gastro-oesophageal reflux disease [DA22] [10]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [10]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [27]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Vasopressin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [28]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Vasopressin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [10]
Clofibrate DMPC1J7 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Clofibrate. Hyper-lipoproteinaemia [5C80] [14]
Methyldopa DM5I621 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Methyldopa. Hypertension [BA00-BA04] [14]
Enalapril DMNFUZR Moderate Increased risk of hyponatremia by the combination of Vasopressin and Enalapril. Hypertension [BA00-BA04] [14]
Fludrocortisone DMUDIR8 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [14]
Meclofenamic acid DM05FXR Moderate Increased risk of hyponatremia by the combination of Vasopressin and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [30]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Polyethylene glycol. Irritable bowel syndrome [DD91] [12]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Vasopressin and Crizotinib. Lung cancer [2C25] [31]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Vasopressin and Ceritinib. Lung cancer [2C25] [10]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Vasopressin and Osimertinib. Lung cancer [2C25] [32]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Vasopressin and Selpercatinib. Lung cancer [2C25] [12]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Vasopressin and Lumefantrine. Malaria [1F40-1F45] [14]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Vasopressin and Halofantrine. Malaria [1F40-1F45] [33]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Vasopressin and Chloroquine. Malaria [1F40-1F45] [34]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Vasopressin and Hydroxychloroquine. Malaria [1F40-1F45] [34]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Quinine. Malaria [1F40-1F45] [10]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Primaquine. Malaria [1F40-1F45] [10]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Vasopressin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [35]
Vincristine DMINOX3 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Vincristine. Mature B-cell lymphoma [2A85] [14]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Vasopressin and Vemurafenib. Melanoma [2C30] [10]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and LGX818. Melanoma [2C30] [36]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Vasopressin and Panobinostat. Multiple myeloma [2A83] [37]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Thalidomide. Multiple myeloma [2A83] [14]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Vasopressin and Siponimod. Multiple sclerosis [8A40] [14]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Vasopressin and Fingolimod. Multiple sclerosis [8A40] [10]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Vasopressin and Ozanimod. Multiple sclerosis [8A40] [38]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Romidepsin. Mycosis fungoides [2B01] [10]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Vasopressin and Nilotinib. Myeloproliferative neoplasm [2A20] [10]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Dasatinib. Myeloproliferative neoplasm [2A20] [39]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Vasopressin and Droperidol. Nausea/vomiting [MD90] [10]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Prochlorperazine. Nausea/vomiting [MD90] [10]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Palonosetron. Nausea/vomiting [MD90] [10]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Granisetron. Nausea/vomiting [MD90] [10]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Vasopressin and Dolasetron. Nausea/vomiting [MD90] [10]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Ondansetron. Nausea/vomiting [MD90] [10]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Entrectinib. Non-small cell lung cancer [2C25] [14]
Urea DMUK75B Moderate Increased risk of hyponatremia by the combination of Vasopressin and Urea. Oesophagitis [DA24] [14]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Vasopressin and Levomethadyl Acetate. Opioid use disorder [6C43] [12]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Lofexidine. Opioid use disorder [6C43] [10]
Rofecoxib DM3P5DA Moderate Increased risk of hyponatremia by the combination of Vasopressin and Rofecoxib. Osteoarthritis [FA00-FA05] [14]
Valdecoxib DMAY7H4 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Valdecoxib. Osteoarthritis [FA00-FA05] [14]
Diclofenac DMPIHLS Moderate Increased risk of hyponatremia by the combination of Vasopressin and Diclofenac. Osteoarthritis [FA00-FA05] [14]
Naproxen DMZ5RGV Moderate Increased risk of hyponatremia by the combination of Vasopressin and Naproxen. Osteoarthritis [FA00-FA05] [14]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Rucaparib. Ovarian cancer [2C73] [10]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Dextropropoxyphene. Pain [MG30-MG3Z] [11]
Etodolac DM6WJO9 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Etodolac. Pain [MG30-MG3Z] [14]
Ibuprofen DM8VCBE Moderate Increased risk of hyponatremia by the combination of Vasopressin and Ibuprofen. Pain [MG30-MG3Z] [14]
Nabumetone DMAT2XH Moderate Increased risk of hyponatremia by the combination of Vasopressin and Nabumetone. Pain [MG30-MG3Z] [14]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Buprenorphine. Pain [MG30-MG3Z] [10]
Tramadol DMRQD04 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Tramadol. Pain [MG30-MG3Z] [10]
Piroxicam DMTK234 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Piroxicam. Pain [MG30-MG3Z] [14]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Triclabendazole. Parasitic worm infestation [1F90] [10]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Pimavanserin. Parkinsonism [8A00] [40]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Apomorphine. Parkinsonism [8A00] [10]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Famotidine. Peptic ulcer [DA61] [14]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Vasopressin and Lefamulin. Pneumonia [CA40] [41]
Ketorolac DMI4EL5 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Ketorolac. Postoperative inflammation [1A00-CA43] [14]
Bromfenac DMKB79O Moderate Increased risk of hyponatremia by the combination of Vasopressin and Bromfenac. Postoperative inflammation [1A00-CA43] [14]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Ritodrine. Preterm labour/delivery [JB00] [18]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Degarelix. Prostate cancer [2C82] [12]
Abarelix DM5WFNP Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Abarelix. Prostate cancer [2C82] [12]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Vasopressin and ABIRATERONE. Prostate cancer [2C82] [12]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Nilutamide. Prostate cancer [2C82] [12]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Enzalutamide. Prostate cancer [2C82] [12]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Flutamide. Prostate cancer [2C82] [12]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Relugolix. Prostate cancer [2C82] [12]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Bicalutamide. Prostate cancer [2C82] [12]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Alfuzosin. Prostate hyperplasia [GA90] [10]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Levomepromazine. Psychotic disorder [6A20-6A25] [10]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Fluphenazine. Psychotic disorder [6A20-6A25] [10]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Triflupromazine. Psychotic disorder [6A20-6A25] [10]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Sorafenib. Renal cell carcinoma [2C90] [10]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Vasopressin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [20]
Meloxicam DM2AR7L Moderate Increased risk of hyponatremia by the combination of Vasopressin and Meloxicam. Rheumatoid arthritis [FA20] [14]
Sulindac DM2QHZU Moderate Increased risk of hyponatremia by the combination of Vasopressin and Sulindac. Rheumatoid arthritis [FA20] [14]
Celecoxib DM6LOQU Moderate Increased risk of hyponatremia by the combination of Vasopressin and Celecoxib. Rheumatoid arthritis [FA20] [14]
Oxaprozin DM9UB0P Moderate Increased risk of hyponatremia by the combination of Vasopressin and Oxaprozin. Rheumatoid arthritis [FA20] [14]
Flurbiprofen DMGN4BY Moderate Increased risk of hyponatremia by the combination of Vasopressin and Flurbiprofen. Rheumatoid arthritis [FA20] [14]
Fenoprofen DML5VQ0 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Fenoprofen. Rheumatoid arthritis [FA20] [14]
Indomethacin DMSC4A7 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Indomethacin. Rheumatoid arthritis [FA20] [14]
Tolmetin DMWUIJE Moderate Increased risk of hyponatremia by the combination of Vasopressin and Tolmetin. Rheumatoid arthritis [FA20] [14]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Quetiapine. Schizophrenia [6A20] [10]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Vasopressin and Mesoridazine. Schizophrenia [6A20] [10]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Vasopressin and Thioridazine. Schizophrenia [6A20] [10]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Aripiprazole. Schizophrenia [6A20] [14]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Vasopressin and Iloperidone. Schizophrenia [6A20] [10]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Paliperidone. Schizophrenia [6A20] [10]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Vasopressin and Haloperidol. Schizophrenia [6A20] [10]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Perphenazine. Schizophrenia [6A20] [10]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Chlorpromazine. Schizophrenia [6A20] [10]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Vasopressin and Clozapine. Schizophrenia [6A20] [10]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Trifluoperazine. Schizophrenia [6A20] [10]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Vasopressin and Ziprasidone. Schizophrenia [6A20] [10]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Risperidone. Schizophrenia [6A20] [10]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Olanzapine. Schizophrenia [6A20] [14]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Vasopressin and Amisulpride. Schizophrenia [6A20] [42]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Asenapine. Schizophrenia [6A20] [10]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Vasopressin and Pimozide. Schizophrenia [6A20] [12]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Vardenafil. Sexual dysfunction [HA00-HA01] [10]
Cyclophosphamide DM4O2Z7 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [14]
Vinblastine DM5TVS3 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Vinblastine. Solid tumour/cancer [2A00-2F9Z] [14]
Ifosfamide DMCT3I8 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [30]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Vasopressin and LEE011. Solid tumour/cancer [2A00-2F9Z] [10]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [10]
Cisplatin DMRHGI9 Moderate Increased risk of hyponatremia by the combination of Vasopressin and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [14]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [12]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [10]
Vinorelbine DMVXFYE Moderate Increased risk of hyponatremia by the combination of Vasopressin and Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [14]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Pitolisant. Somnolence [MG42] [10]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [10]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Vasopressin and Ibutilide. Supraventricular tachyarrhythmia [BC81] [10]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Vasopressin and Adenosine. Supraventricular tachyarrhythmia [BC81] [10]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Zithromax. Syphilis [1A61-1A6Z] [10]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Vasopressin and Anagrelide. Thrombocytosis [3B63] [10]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Lenvatinib. Thyroid cancer [2D10] [10]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Vasopressin and Cabozantinib. Thyroid cancer [2D10] [12]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Vasopressin and Papaverine. Tonus and reflex abnormality [MB47] [43]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Tizanidine. Tonus and reflex abnormality [MB47] [10]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Tacrolimus. Transplant rejection [NE84] [10]
Chlorpropamide DMPHZQE Moderate Increased risk of hyponatremia by the combination of Vasopressin and Chlorpropamide. Type 2 diabetes mellitus [5A11] [14]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Astemizole. Vasomotor/allergic rhinitis [CA08] [10]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [11]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Vasopressin and Disopyramide. Ventricular tachyarrhythmia [BC71] [10]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Vasopressin and Procainamide. Ventricular tachyarrhythmia [BC71] [10]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Propafenone. Ventricular tachyarrhythmia [BC71] [10]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Vasopressin and Flecainide. Ventricular tachyarrhythmia [BC71] [10]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Vasopressin and Amiodarone. Ventricular tachyarrhythmia [BC71] [10]
⏷ Show the Full List of 241 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2168).
2 Vasopressin FDA Label
3 BDDCS applied to over 900 drugs
4 FDA Approved Drug Products: VASOSTRICT (vasopressin) injection
5 Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
6 Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41.
7 Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
8 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
9 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
10 Canadian Pharmacists Association.
11 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
12 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
14 Cerner Multum, Inc. "Australian Product Information.".
15 European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine.".
16 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
18 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
19 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
20 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
21 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
23 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
24 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
25 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
26 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
27 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
28 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
29 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
30 Vanhees SL, Paridaens R, Vansteenkiste JF "Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review." Ann Oncol 11 (2000): 1061-5. [PMID: 11038047]
31 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
33 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
34 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
35 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
36 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
37 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
38 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
39 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
40 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
41 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
42 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
43 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]